Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Selective inhibitor studies in macrophages implicate class II HDAC enzymes in TLR-mediated inflammatory pathways and class I HDACs as negative regulators. Broad-spectrum inhibitors of HDACs are therapeutic in many inflammatory disease models but exacerbated disease in a mouse model of atherosclerosis. HDAC inhibitors have anti- and proinflammatory effects on macrophages in vitro. We report here that several broad-spectrum HDAC inhibitors, including TSA and SAHA, suppressed the LPS-induced mRNA expression of the proinflammatory mediators Edn-1, Ccl-7/MCP-3, and Il-12p40 but amplified the expression of the proatherogenic factors Cox-2 and Pai-1/serpine1 in primary mouse BMM. Similar effects were also apparent in LPS-stimulated TEPM and HMDM. The pro- and anti-inflammatory effects of TSA were separable over a concentration range, implying that individual HDACs have differential effects on macrophage inflammatory responses. The HDAC1-selective inhibitor, MS-275, retained proinflammatory effects (amplification of LPS-induced expression of Cox-2 and Pai-1 in BMM) but suppressed only some inflammatory responses. In contrast, 17a (a reportedly HDAC6-selective inhibitor) retained anti-inflammatory but not proinflammatory properties. Despite this, HDAC6−/− macrophages showed normal LPS-induced expression of HDAC-dependent inflammatory genes, arguing that the anti-inflammatory effects of 17a are not a result of inhibition of HDAC6 alone. Thus, 17a provides a tool to identify individual HDACs with proinflammatory properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As drug inhibition of cellular deacetylases strongly attenuates pathogen-and immunogen-induced immune responses (139–141), it is tempting to speculate that acetylation plays a key role in modulating immune signaling pathways.”
From The Impact of Mass Spectrometry–Based Proteomics on Fundamental Discoveries in Virology (2014) · cites this paper as [139]
Citations
Cites
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease
Segain, J.-P., de la Blétière, D. R., Bourreille, A., Leray, V, Gervois, N., Rosales, C., Ferrier, L., Bonnet, C., Blottière, H. M., & Galmiche, J.-P. (2000) · Gut · doi:10.1136/gut.47.3.397 · Cited by 1,321
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760 · cited 2×
“To assess the selectivity of MS-275, compound 17a, and compound 7 in macrophages, we first examined the hyperacetylation of HDAC substrates, HDAC1 and HDAC6 deacetylate histone H3, [35] and -tubulin [39], respectively.”
BackgroundIto, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P. J., & Adcock, I. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050466 · Cited by 638
Histone acetylation and deacetylation: importance in inflammatory lung diseases
Barnes, P. J., Adcock, I. M., & Ito, K. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00117504 · Cited by 564
Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally
Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Li, N., Cheng, H.-L., Chua, K., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01154-06 · Cited by 559 · cited 1×
“To assess the selectivity of MS-275, compound 17a, and compound 7 in macrophages, we first examined the hyperacetylation of HDAC substrates, HDAC1 and HDAC6 deacetylate histone H3, [35] and -tubulin [39], respectively.”
BackgroundSelf-citationKim, H. J., Rowe, M., Ren, M., Hong, J.-S., Chen, P.-S., & Chuang, D.-M. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120188 · Cited by 557
Leoni, F., Zaliani, A., Bertolini, G., Porro, G., Pagani, P., Pozzi, P., Donà, G., Fossati, G., Sozzani, S., Azam, T., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052702999 · Cited by 508
Peyssonnaux, C., Cejudo-Martin, P., Doedens, A., Zinkernagel, A. S., Johnson, R. S., & Nizet, V. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7516 · Cited by 480 · cited 1×
“bilize the transcription factor HIF-1 and promote its transcriptional activity [36], and because HIF-1 is a key transcription factor in TLR signaling pathways and inflammatory responses in macrophages in vitro and in vivo [37, 38].”
BackgroundBlouin, C. C., Pagé, E. L., Soucy, G. M., & Richard, D. E. (2004) · Blood · doi:10.1182/blood-2003-07-2427 · Cited by 458
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Villagra, A., Cheng, F., Wang, H.-W., Suarez, I., Glozak, M., Maurin, M., Nguyen, D., Wright, K. L., Atadja, P. W., Bhalla, K., et al. (2009) · Nature Immunology · doi:10.1038/ni.1673 · Cited by 455
Cipollone, F., Prontera, C., Pini, B., Marini, M., Fazia, M., De Cesare, D., Iezzi, A., Ucchino, S., Boccoli, G., Saba, V., et al. (2001) · Circulation · doi:10.1161/hc3401.093152 · Cited by 351
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Duvic, M., & Vu, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1111 · Cited by 344
Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P., & Pili, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4598 · Cited by 299
Camelo, S., Iglesias, A. H., Hwang, D., Due, B., Ryu, H., Smith, K., Gray, S. G., Imitola, J., Duran, G., Assaf, B., et al. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.02.022 · Cited by 275
Lin, H., Hu, C., Chan, H., Liew, Y., Huang, H., Lepescheux, L., Bastianelli, E., Baron, R., Rawadi, G., & Clément‐Lacroix, P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707165 · Cited by 272
Chung, Y.-L., Lee, M.-Y., Wang, A.-J., & Yao, L.-F. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00235-1 · Cited by 253
Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?
Blanchard, F., & Chipoy, C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03309-4 · Cited by 239
Aung, H. T., Schroder, K., Himes, S. R., Brion, K., Van Zuylen, W., Trieu, A., Suzuki, H., Hayashizaki, Y., Hume, D. A., Sweet, M. J., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-5360com · Cited by 229
Self-citationBrogdon, J. L., Xu, Y., Szabo, S. J., An, S., Buxton, F., Cohen, D., & Huang, Q. (2007) · Blood · doi:10.1182/blood-2006-04-019711 · Cited by 227
Grabiec, A. M., Krausz, S., de Jager, W., Burakowski, T., Groot, D., Sanders, M. E., Prakken, B. J., Maslinski, W., Eldering, E., Tak, P. P., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901467 · Cited by 224
Histone Deacetylase Inhibitors In Inflammatory Disease
Halili, M., Andrews, M., Sweet, M., & Fairlie, D. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609788085250 · Cited by 198
Self-citationAcetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling
Cao, W., Bao, C., Padalko, E., & Lowenstein, C. J. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071728 · Cited by 190
Kozikowski, A. P., Tapadar, S., Luchini, D. N., Kim, K. H., & Billadeau, D. D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002894 · Cited by 189
Trichostatin A attenuates airway inflammation in mouse asthma model
Choi, J. ‐., Oh, S. ‐., Kang, M. ‐., Kwon, H. J., Oh, G. ‐., & Kim, D. ‐. (2005) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.02006.x · Cited by 183
Bode, K. A., Schroder, K., Hume, D. A., Ravasi, T., Heeg, K., Sweet, M. J., & Dalpke, A. H. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02678.x · Cited by 180
Self-citationPorcu, M., & Chiarugi, A. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.009 · Cited by 173
Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators
Deng, W.-G., Zhu, Y., & Wu, K. K. (2004) · Blood · doi:10.1182/blood-2003-09-3131 · Cited by 142
Trichostatin A Exacerbates Atherosclerosis in Low Density Lipoprotein Receptor–Deficient Mice
Choi, J.-H., Nam, K.-H., Kim, J., Baek, M. W., Park, J.-E., Park, H.-Y., Kwon, H. J., Kwon, O.-S., Kim, D.-Y., & Oh, G. T. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000184758.07257.88 · Cited by 141
Nusinzon, I., & Horvath, C. M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.3106-3113.2006 · Cited by 139
Regulation of microglial inflammatory response by histone deacetylase inhibitors
Suuronen, T., Huuskonen, J., Pihlaja, R., Kyrylenko, S., & Salminen, A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02004.x · Cited by 124
Suzuki, T., Kouketsu, A., Itoh, Y., Hisakawa, S., Maeda, S., Yoshida, M., Nakagawa, H., & Miyata, N. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060554y · Cited by 105
Gómez‐Hernández, A., Martín-Ventura, J. L., Sánchez-Galán, E., Vidal, C., Ortego, M., Blanco‐Colio, L. M., Ortega, L. M., Tuñón, J., & Egido, J. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.08.035 · Cited by 98
Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis
Jüngel, A., Barešová, V., Ospelt, C., Simmen, B. R., Michel, B. A., Gay, R. E., Gay, S., Seemayer, C. A., & Neidhart, M. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044065 · Cited by 89
Plasminogen Activator Inhibitor-1 in Vascular Thrombosis
Westrick, R. J., & Eitzman, D. T. (2007) · Current Drug Targets · doi:10.2174/138945007781662328 · Cited by 85
Wang, J., Mahmud, S. A., Bitterman, P. B., Huo, Y., & Slungaard, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703586200 · Cited by 65
Loss of PU.1 Expression Following Inhibition of Histone Deacetylases
Laribee, R. N., & Klemsz, M. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5160 · Cited by 64
Inhibition of iNOS expression and NO production by anti-inflammatory steroids
Hämäläinen, M., Lilja, R., Kankaanranta, H., & Moilanen, E. (2007) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2007.08.003 · Cited by 60
PU.1 and ICSBP control constitutive and IFN-γ-regulated Tlr9 gene expression in mouse macrophages
Schroder, K., Lichtinger, M., Irvine, K. M., Brion, K., Trieu, A., Ross, I. L., Ravasi, T., Stacey, K. J., Rehli, M., Hume, D. A., et al. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0107036 · Cited by 51
Self-citationSchroder, K., Spille, M., Pilz, A., Lattin, J., Bode, K. A., Irvine, K. M., Burrows, A. D., Ravasi, T., Weighardt, H., Stacey, K. J., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3495 · Cited by 44
Self-citationErythroid Kruppel-like Factor Regulates the G1 Cyclin Dependent Kinase Inhibitor p18INK4c
Tallack, M. R., Keys, J. R., & Perkins, A. C. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.109 · Cited by 41
Lu, S., Wu, H.-W., Lin, Y.-J., & Chang, S. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00031.2009 · Cited by 37
ATF-2 regulates lipopolysaccharide-induced transcription in macrophage cells
Hirose, N., Maekawa, T., Shinagawa, T., & Ishii, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.05.001 · Cited by 35
Chung, Yl, Lee, My, Wang, Aj, & Yao (2006) · 中国生物学文摘 · Cited by 34
Inhibitors of Histone Deacetylases as Anti-inflammatory Drugs
Dinarello, C. A. (2006) · Springer eBooks · doi:10.1007/3-540-37673-9_3 · Cited by 21
Histone H4 HDAC activity is necessary for expression of the PU.1 gene
Laribee, R. N., & Klemsz, M. J. (2005) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2005.08.003 · Cited by 11 · cited 1×
“1 locus correlated with expression of this gene [50].”
Background
Cited by
Regulation of inflammation by short chain fatty acids
Vinolo, M. A. R., Rodrigues, H. G., Nachbar, R. T., & Curi, R. (2011) · Nutrients · doi:10.3390/nu3100858 · Cited by 1,724
Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells
Li, M., van Esch, B. C. A. M., Wagenaar, G. T. M., Garssen, J., Folkerts, G., & Henricks, P. A. J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.003 · Cited by 614
Histone deacetylases as regulators of inflammation and immunity
Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., & Sweet, M. J. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.04.001 · Cited by 546
Self-citationHDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
Yoon, S., & Eom, G. H. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.1.1 · Cited by 464
Regulation of short-chain fatty acids in the immune system
Liu, X.-F., Shao, J.-H., Liao, Y.-T., Wang, L.-N., Jia, Y., Dong, P.-J., Liu, Z.-Z., He, D.-D., Li, C., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1186892 · Cited by 403
Metadata
- Authors
- Halili, M. A., Andrews, M. R., Labzin, L. I., Schroder, K., Matthias, G., Cao, C., Lovelace, E., Reid, R. C., Le, G. T., Hume, D. A., Irvine, K. M., Matthias, P., Fairlie, D. P., & Sweet, M. J.
- Affiliations
- The University of Queensland (AU)
- University of Lausanne (CH)
- Friedrich Miescher Institute (CH)
- Roslin Institute (GB)
- Corresponding author
- Sweet, Matthew J
- ORCID
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-03-03
- Volume
- 87
- Issue
- 6
- Pages
- 1103-1114
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2114231153
- Cited by
- 186
- References
- 51
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 9 · 2022: 8 · 2021: 11 · 2020: 16 · 2019: 5 · 2018: 13 · 2017: 8 · 2016: 26 · 2015: 15 · 2014: 13 · 2013: 17 · 2012: 16
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Leukocyte Biology (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- ARC Special Research Centre for Functional and Applied Genomics
- Cancer Council Queensland (511205)
- Australian National Health and Medical Research Council (569735)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Keywords
- histone deacetylase inhibitors, macrophage inflammation, TLR4, lipopolysaccharide, atherosclerosis, trichostatin A, vorinostat, entinostat, HDAC6, HDAC1, cyclooxygenase-2, plasminogen activator inhibitor-1, IL-12, macrophages
- MeSH terms
- Histone Deacetylase 6, Vorinostat, Animals, Enzyme-Linked Immunosorbent Assay, Histone Deacetylases, Hydroxamic Acids, Inflammation, Lipopolysaccharides, Luciferases, Macrophages, Male, Mice, Inbred C57BL, RNA, Messenger, Blotting, Western, Plasminogen Activator Inhibitor 1, Mice, Knockout, Inflammation Mediators, Reverse Transcriptase Polymerase Chain Reaction, Chromatin Immunoprecipitation, Toll-Like Receptor 4, Mice, Cyclooxygenase 2, Interleukin-12 Subunit p40, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.